3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
INDIV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Leukemia, Myeloid, Chronic-Phase
3
Leukemia, Myeloid, Acute
2
Leukemia, Myeloid, Accelerated Phase
2
Blast Crisis
2
Retroperitoneal liposarcoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Mastocytosis, Systemic
1
Liposarcoma
1
Leukemia
1
Leiomyosarcoma
1
Hypereosinophilic Syndrome
1
Chondrosarcoma
1
Interventions
toripalimab
2
Trabectedin
2
Doxorubicin
2
Docetaxel
2
Biopsy
2
temsirolimus
1
silmitasertib
1
selinexor
1
pazopanib
1
palbociclib
1
nilotinib
1
mirdametinib
1
liposomal doxorubicin
1
lenvatinib
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
eribulin
1
cemiplimab
1
avelumab
1
abemaciclib
1
Vincristine
1
Temozolomide
1
Specimen Handling
1
Reverse Transcriptase Polymerase Chain Reaction
1
Radiotherapy
1
Proton Therapy
1
Nelfinavir
1
Irinotecan
1
Immunoenzyme Techniques
1
Imatinib Mesylate
1
Ifosfamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Liposarcoma
×
nilotinib
×
Clear all
NCT02587169
2015-10-27
GEIS-27
Broto, Javier MartÃn, M.D.
Phase 1/2
Unknown
40 enrolled